[Real-world evidence and randomized controlled trials: the initiation, implementation, progress interpretation and revelation of RCT DUPLICATE (part 1)]

Zhonghua Liu Xing Bing Xue Za Zhi. 2022 Nov 10;43(11):1828-1834. doi: 10.3760/cma.j.cn112338-20220513-00408.
[Article in Chinese]

Abstract

In recent years, researchers, pharmaceutical companies, and political makers gradually using more real-world data (RWD) to produce real-world evidence (RWE) for policy-making. A research team of Harvard University launched the RCT DUPLICATE project in 2018, aiming to replicate 30 randomized controlled trials using the medical claims database in order to explore methods for quantifying the efficacy-effectiveness gap and explain its potential sources, to enhance the credibility of the RWE. This paper reviews the background of RCT DUPLICATE Initiative, highlights the research purposes, research design and implementation process of the RCT DUPLICATE Initiative, to help domestic scholars better understand the scope and application value of RWE.

近些年,医疗产品监管机构开始重新审视真实世界证据(RWE)对监管决策的潜在价值。RWE能否代替金标准随机对照试验(RCT)产生的证据尚不确定。哈佛大学研究团队于2018年发起了RCT DUPLICATE项目,旨在利用医疗索赔数据库模拟30个RCT,以探索效力-效果差距的量化方法并解释其潜在来源,增强RWE的可信度。本文回顾了RCT DUPLICATE项目的产生背景,重点介绍RCT DUPLICATE项目的研究目的、研究设计和实施流程,以期帮助国内学者更好地理解RWE的适用范围和应用价值。.

Publication types

  • Review
  • English Abstract

MeSH terms

  • Cognition*
  • Databases, Factual
  • Humans
  • Randomized Controlled Trials as Topic
  • Research Personnel*
  • Universities